{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:30Z","timestamp":1792723110680,"version":"4.5.0"},"reference-count":167,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neurot.2026.e01035","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T06:09:52Z","timestamp":1787378992000},"page":"e01035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design"],"prefix":"10.1016","volume":"23","author":[{"given":"George","family":"Nageeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Adam","family":"Sjoholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.neurot.2026.e01035_bib1","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01035_bib2","first-page":"299","article-title":"Management of glioblastoma: state of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01035_bib3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01035_bib4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01035_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-Mutant low-grade glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01035_bib6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"112","key":"10.1016\/j.neurot.2026.e01035_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ads0449","article-title":"The immunology of brain tumors","volume":"10","author":"Bunse","year":"2025","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.neurot.2026.e01035_bib9","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013Positive Non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.neurot.2026.e01035_bib10","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic Non\u2013small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.neurot.2026.e01035_bib11","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01035_bib12","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01035_bib13","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1038\/s41591-024-03152-x","article-title":"Cranioencephalic functional lymphoid units in glioblastoma","volume":"30","author":"Dobersalske","year":"2024","journal-title":"Nat Med"},{"issue":"7792","key":"10.1016\/j.neurot.2026.e01035_bib14","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41586-019-1912-x","article-title":"VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours","volume":"577","author":"Song","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib15","article-title":"The immune landscape of cerebrospinal fluid across brain malignancies","volume":"8","author":"Kim","year":"2026","journal-title":"Neurooncol Adv"},{"issue":"8044","key":"10.1016\/j.neurot.2026.e01035_bib16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41586-024-08279-y","article-title":"Endogenous self-peptides guard immune privilege of the central nervous system","volume":"637","author":"Kim","year":"2025","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01035_bib17","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1016\/j.immuni.2025.09.018","article-title":"Spatial immune profiling defines a subset of human gliomas with functional tertiary lymphoid structures","volume":"58","author":"Cakmak","year":"2025","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01035_bib18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(24)00735-6","article-title":"Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study","volume":"26","author":"Long","year":"2025","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01035_bib19","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01035_bib20","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/j.immuni.2024.09.003","article-title":"T lymphocyte recruitment to melanoma brain tumors depends on distinct venous vessels","volume":"57","author":"Messmer","year":"2024","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01035_bib21","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.cell.2020.12.040","article-title":"Functional characterization of the dural sinuses as a neuroimmune interface","volume":"184","author":"Rustenhoven","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib22","article-title":"Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes","volume":"3","author":"Blobner","year":"2021","journal-title":"Neuro Oncol Adv"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2326-6066.CIR-22-0098","article-title":"The conventional dendritic cell 1 subset primes CD8+ T cells and traffics tumor antigen to drive antitumor immunity in the brain","volume":"11","author":"Bowman-Kirigin","year":"2023","journal-title":"Cancer Immunol Res"},{"issue":"6553","key":"10.1016\/j.neurot.2026.e01035_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf7844","article-title":"Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma","volume":"373","author":"Cugurra","year":"2021","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01035_bib25","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/s41593-018-0213-2","article-title":"Direct vascular channels connect skull bone marrow and the brain surface enabling myeloid cell migration","volume":"21","author":"Herisson","year":"2018","journal-title":"Nat Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-66985-1","article-title":"Pericytes orchestrate a tumor-restraining microenvironment in glioblastoma","volume":"16","author":"Braun","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41525-023-00381-w","article-title":"CNS tumor stroma transcriptomics identify perivascular fibroblasts as predictors of immunotherapy resistance in glioblastoma patients","volume":"8","author":"Zarodniuk","year":"2023","journal-title":"npj Genom Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s43018-025-01097-9","article-title":"Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity","volume":"7","author":"Moreno-Sanchez","year":"2026","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/cells10010018","article-title":"Myeloid cells in glioblastoma microenvironment","volume":"10","author":"De Leo","year":"2020","journal-title":"Cells"},{"issue":"6731","key":"10.1016\/j.neurot.2026.e01035_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/science.abm5214","article-title":"Distinct myeloid-derived suppressor cell populations in human glioblastoma","volume":"387","author":"Jackson","year":"2025","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01035_bib31","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","article-title":"Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells","volume":"181","author":"Klemm","year":"2020","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.neurot.2026.e01035_bib32","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.3390\/cancers13236092","article-title":"Tumor mutation burden, expressed neoantigens and the immune microenvironment in diffuse gliomas","volume":"13","author":"Yu","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"399","key":"10.1016\/j.neurot.2026.e01035_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01035_bib34","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","article-title":"Glioblastoma at the crossroads: current understanding and future therapeutic horizons","volume":"10","author":"Singh","year":"2025","journal-title":"Signal Transduct Targeted Ther"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01035_bib36","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00701-022-05301-y","article-title":"The WHO 2021 classification of central nervous system tumours: a practical update on what neurosurgeons need to know\u2014a minireview","volume":"164","author":"Torp","year":"2022","journal-title":"Acta Neurochir"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib37","article-title":"Tumor microenvironment in glioblastoma: current and emerging concepts","volume":"5","author":"Sharma","year":"2023","journal-title":"Neurooncol Adv"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib38","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41467-022-28523-1","article-title":"T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10","volume":"13","author":"Ravi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurot.2026.e01035_bib39","article-title":"Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies","volume":"vol. 9","author":"Pombo Antunes","year":"2020"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01035_bib40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2026.e01035_bib41","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s12967-020-02598-0","article-title":"Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight","volume":"18","author":"Land","year":"2020","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib42","article-title":"Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma","volume":"5","author":"Schmidts","year":"2022","journal-title":"Neurooncol Adv"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41698-024-00646-2","article-title":"Treatment of IDH-mutant glioma in the INDIGO era","volume":"8","author":"Lin","year":"2024","journal-title":"npj Precis Onc"},{"issue":"7854","key":"10.1016\/j.neurot.2026.e01035_bib44","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","article-title":"A vaccine targeting mutant IDH1 in newly diagnosed glioma","volume":"592","author":"Platten","year":"2021","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01035_bib45","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/s41591-023-02555-6","article-title":"A H3K27M-targeted vaccine in adults with diffuse midline glioma","volume":"29","author":"Grassl","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01035_bib46","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.trecan.2022.12.008","article-title":"T cell exhaustion in malignant gliomas","volume":"9","author":"Watowich","year":"2023","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib47","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163446","article-title":"Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy","volume":"133","author":"Khan","year":"2023","journal-title":"J Clin Investig"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01035_bib48","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.it.2021.02.004","article-title":"Context-dependent glioblastoma\u2013macrophage\/microglia symbiosis and associated mechanisms","volume":"42","author":"Xuan","year":"2021","journal-title":"Trends Immunol"},{"key":"10.1016\/j.neurot.2026.e01035_bib49","article-title":"The role of myeloid cells in GBM immunosuppression","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2026.e01035_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105190","article-title":"Molecular heterogeneity of Glioblastoma-associated microglia and macrophages and myeloid-derived suppressor cells: insights from single-cell omics and therapeutic implications","volume":"220","author":"Kumar","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01035_bib51","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","article-title":"Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization","volume":"24","author":"Pombo Antunes","year":"2021","journal-title":"Nat Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib52","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13059-017-1362-4","article-title":"Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment","volume":"18","author":"M\u00fcller","year":"2017","journal-title":"Genome Biol"},{"issue":"15","key":"10.1016\/j.neurot.2026.e01035_bib53","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1042\/CS20220531","article-title":"M1\/M2 macrophages and their overlaps \u2013 myth or reality?","volume":"137","author":"Strizova","year":"2023","journal-title":"Clin Sci"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01035_bib54","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1189\/jlb.0103010","article-title":"Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species","volume":"74","author":"Kusmartsev","year":"2003","journal-title":"J Leukoc Biol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Targeted Ther"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01035_bib56","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","article-title":"TREM2 modulation remodels the tumor myeloid landscape enhancing Anti-PD-1 immunotherapy","volume":"182","author":"Molgora","year":"2020","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.neurot.2026.e01035_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade3559","article-title":"TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma","volume":"9","author":"Sun","year":"2023","journal-title":"Sci Adv"},{"issue":"7368","key":"10.1016\/j.neurot.2026.e01035_bib58","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nature10491","article-title":"An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor","volume":"478","author":"Opitz","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01035_bib59","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/metabo16030185","article-title":"Nexus of IDO1\/Kynurenine pathway to T-Cell exhaustion: hypoxia-induced tryptophan metabolism in glioblastoma","volume":"16","author":"Abikenari","year":"2026","journal-title":"Metabolites"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01035_bib60","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41593-019-0370-y","article-title":"Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39","volume":"22","author":"Takenaka","year":"2019","journal-title":"Nat Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib61","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","article-title":"Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine","volume":"11","author":"Campesato","year":"2020","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01035_bib62","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.immuni.2024.04.006","article-title":"Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma","volume":"57","author":"De Leo","year":"2024","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01035_bib63","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41556-025-01839-y","article-title":"Inhibiting macrophage-derived lactate transport restores cGAS\u2013STING signalling and enhances antitumour immunity in glioblastoma","volume":"28","author":"Li","year":"2026","journal-title":"Nat Cell Biol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01035_bib64","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1084\/jem.20100587","article-title":"HIF-1\u03b1 regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment","volume":"207","author":"Corzo","year":"2010","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib65","article-title":"Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2\u03b1","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01035_bib66","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01035_bib67","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1391973","article-title":"Blocking the CD47-SIRP\u03b1 axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells","volume":"7","author":"Li","year":"2017","journal-title":"OncoImmunology"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01035_bib68","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1073\/pnas.1721434116","article-title":"Microglia are effector cells of CD47-SIRP\u03b1 antiphagocytic axis disruption against glioblastoma","volume":"116","author":"Hutter","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01035_bib69","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","article-title":"Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors","volume":"24","author":"Chongsathidkiet","year":"2018","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01035_bib70","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41423-024-01202-5","article-title":"Targeting the glucocorticoid receptor-CCR8 axis mediated bone marrow T cell sequestration enhances infiltration of anti-tumor T cells in intracranial cancers","volume":"21","author":"Zhang","year":"2024","journal-title":"Cell Mol Immunol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e01035_bib71","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1093\/brain\/awaa343","article-title":"Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators","volume":"143","author":"Ayasoufi","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2026.e01035_bib72","article-title":"Enhancing T cell infiltration in glioblastoma: a review article on challenges and therapeutic strategies","volume":"45","author":"Habibi","year":"2025","journal-title":"Cancer Treat Res Commun"},{"issue":"21","key":"10.1016\/j.neurot.2026.e01035_bib73","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.3390\/cancers13215367","article-title":"Enhancing T cell chemotaxis and infiltration in glioblastoma","volume":"13","author":"Singh","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.neurot.2026.e01035_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.850226","article-title":"Characterising distinct migratory profiles of infiltrating T-Cell subsets in human glioblastoma","volume":"13","author":"Kollis","year":"2022","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.neurot.2026.e01035_bib75","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1158\/1078-0432.CCR-17-2617","article-title":"Immunophenotyping of newly diagnosed and recurrent glioblastoma defines distinct immune exhaustion profiles in peripheral and tumor-infiltrating lymphocytes","volume":"24","author":"Mohme","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.neurot.2026.e01035_bib76","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","article-title":"T-Cell exhaustion signatures vary with tumor type and are severe in glioblastoma","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib77","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.immuni.2024.11.026","article-title":"Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion","volume":"58","author":"Waibl Polania","year":"2025","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01035_bib78","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-3083.2009.02308.x","article-title":"How do regulatory T cells work?","volume":"70","author":"Corthay","year":"2009","journal-title":"Scand J Immunol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01035_bib79","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.immuni.2025.03.021","article-title":"Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies","volume":"58","author":"Galvez-Cancino","year":"2025","journal-title":"Immunity"},{"issue":"19","key":"10.1016\/j.neurot.2026.e01035_bib80","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","article-title":"CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells","volume":"76","author":"Chang","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib81","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4049\/jimmunol.1103248","article-title":"Tumor-associated microglia\/macrophages enhance the invasion of glioma stem-like cells via TGF-\u03b21 signaling pathway","volume":"189","author":"zong","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.neurot.2026.e01035_bib82","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.clineuro.2013.12.004","article-title":"The role of regulatory T-cells in glioma immunology","volume":"119","author":"Ooi","year":"2014","journal-title":"Clin Neurol Neurosurg"},{"issue":"14","key":"10.1016\/j.neurot.2026.e01035_bib83","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142116","article-title":"Targeting the \u03b1v integrin\/TGF-\u03b2 axis improves natural killer cell function against glioblastoma stem cells","volume":"131","author":"Shaim","year":"2021","journal-title":"J Clin Investig"},{"issue":"20","key":"10.1016\/j.neurot.2026.e01035_bib84","doi-asserted-by":"crossref","first-page":"7596","DOI":"10.1158\/0008-5472.CAN-04-1627","article-title":"RNA interference targeting transforming growth Factor-\u03b2 enhances NKG2D-Mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo","volume":"64","author":"Friese","year":"2004","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01035_bib85","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1093\/brain\/awl205","article-title":"TGF- and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells","volume":"129","author":"Eisele","year":"2006","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-10680-4","article-title":"Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas","volume":"12","author":"S\u00f6nmez","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib87","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/cei.13476","article-title":"Suppressor of cytokine signaling 1 inhibits the maturation of dendritic cells involving the nuclear factor kappa B signaling pathway in the glioma microenvironment","volume":"202","author":"He","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.neurot.2026.e01035_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578147","article-title":"Human dendritic cell subsets in the glioblastoma-associated microenvironment","volume":"383","author":"Hu","year":"2023","journal-title":"J Neuroimmunol"},{"issue":"21","key":"10.1016\/j.neurot.2026.e01035_bib89","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1016\/j.cell.2023.08.043","article-title":"The local microenvironment drives activation of neutrophils in human brain tumors","volume":"186","author":"Maas","year":"2023","journal-title":"Cell"},{"issue":"46","key":"10.1016\/j.neurot.2026.e01035_bib91","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1038\/s41388-020-01506-6","article-title":"Tenascin C promotes cancer cell plasticity in mesenchymal glioblastoma","volume":"39","author":"Angel","year":"2020","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01035_bib92","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1021\/nl403266t","article-title":"T cell activation is determined by the number of presented antigens","volume":"13","author":"Deeg","year":"2013","journal-title":"Nano Lett"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01035_bib93","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-18-0599","article-title":"Reduced neoantigen expression revealed by longitudinal multiomics as a possible immune evasion mechanism in glioma","volume":"7","author":"Nejo","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib94","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41467-020-20469-6","article-title":"Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy","volume":"12","author":"Gromeier","year":"2021","journal-title":"Nat Commun"},{"issue":"6190","key":"10.1016\/j.neurot.2026.e01035_bib95","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel","year":"2014","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib96","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/neuonc\/nou158","article-title":"TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas","volume":"17","author":"Simon","year":"2015","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib97","first-page":"359","article-title":"Survivin is a prognostic indicator in glioblastoma and may be a target of microRNA-218","volume":"18","author":"Tong","year":"2019","journal-title":"Oncol Lett"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01035_bib98","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41590-022-01215-0","article-title":"Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression","volume":"23","author":"Yeo","year":"2022","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e01035_bib99","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1158\/2326-6066.CIR-22-0655","article-title":"Driver mutations dictate the immunologic landscape and response to checkpoint immunotherapy of glioblastoma","volume":"11","author":"Yeo","year":"2023","journal-title":"Cancer Immunol Res"},{"issue":"7514","key":"10.1016\/j.neurot.2026.e01035_bib100","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nature13387","article-title":"A vaccine targeting mutant IDH1 induces antitumour immunity","volume":"512","author":"Schumacher","year":"2014","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01035_bib101","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7804","key":"10.1016\/j.neurot.2026.e01035_bib102","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and therapeutic implications of hypermutation in gliomas","volume":"580","author":"Touat","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01035_bib103","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1101\/gr.180612.114","article-title":"Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution","volume":"25","author":"Kim","year":"2015","journal-title":"Genome Res"},{"issue":"6280","key":"10.1016\/j.neurot.2026.e01035_bib104","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01035_bib105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","article-title":"Comprehensive analysis of alternative splicing across tumors from 8,705 patients","volume":"34","author":"Kahles","year":"2018","journal-title":"Cancer Cell"},{"issue":"470","key":"10.1016\/j.neurot.2026.e01035_bib106","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5516","article-title":"Noncoding regions are the main source of targetable tumor-specific antigens","volume":"10","author":"Laumont","year":"2018","journal-title":"Sci Transl Med"},{"issue":"8054","key":"10.1016\/j.neurot.2026.e01035_bib107","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-024-08552-0","article-title":"Tumour-wide RNA splicing aberrations generate actionable public neoantigens","volume":"639","author":"Kwok","year":"2025","journal-title":"Nature"},{"issue":"147","key":"10.1016\/j.neurot.2026.e01035_bib108","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003748","article-title":"A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid \u03b2","volume":"4","author":"Iliff","year":"2012","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01035_bib109","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/ana.24271","article-title":"Impairment of paravascular clearance pathways in the aging brain","volume":"76","author":"Kress","year":"2014","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib110","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1940673","article-title":"Sustained localized delivery of immunotherapy to lymph nodes reverses immunosuppression and increases long-term survival in murine glioblastoma","volume":"10","author":"Choi","year":"2026","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01035_bib111","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","article-title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib112","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/imm.70027","article-title":"Tertiary lymphoid structures predict prognosis and immune checkpoint inhibitor efficacy in lung squamous cell carcinoma","volume":"177","author":"Chen","year":"2026","journal-title":"Immunology"},{"key":"10.1016\/j.neurot.2026.e01035_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1166497","article-title":"Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma","volume":"14","author":"Shang","year":"2023","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01035_bib114","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of Nivolumab vs Bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01035_bib116","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01035_bib117","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41590-019-0433-y","article-title":"Mechanisms of immunotherapy resistance: lessons from glioblastoma","volume":"20","author":"Jackson","year":"2019","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01035_bib118","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163447","article-title":"Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment","volume":"133","author":"Arrieta","year":"2023","journal-title":"J Clin Investig"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01035_bib119","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1158\/2326-6066.CIR-23-0959","article-title":"Nivolumab reaches brain lesions in patients with recurrent glioblastoma and induces T-cell activity and upregulation of checkpoint pathways","volume":"12","author":"Skadborg","year":"2024","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01035_bib120","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib121","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54326-7","article-title":"Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort","volume":"15","author":"McFaline-Figueroa","year":"2024","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01035_bib122","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","article-title":"Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma","volume":"25","author":"Schalper","year":"2019","journal-title":"Nat Med"},{"issue":"suppl ment_5","key":"10.1016\/j.neurot.2026.e01035_bib123","article-title":"CTIM-12. Dual immune checkpoint blockade for surgically accessible recurrent glioblastoma: clinical and molecular outcomes","volume":"27","author":"Sun","year":"2025","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01035_bib124","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.22.00996","article-title":"Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma","volume":"41","author":"Ahluwalia","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement_2","key":"10.1016\/j.neurot.2026.e01035_bib125","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/neuonc\/noad137.008","article-title":"KS01.6.A UCPVAX-GLIO: a phase II trial evaluating the immunogenicity and efficacy of an anti-telomerase vaccine in patients with newly diagnosed GBM","volume":"25","author":"Carpentier","year":"2023","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e01035_bib126","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/neuonc\/noz040","article-title":"Phase I\/II trial testing safety and immunogenicity of the multipeptide IMA950\/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients","volume":"21","author":"Migliorini","year":"2019","journal-title":"Neuro Oncol"},{"issue":"19","key":"10.1016\/j.neurot.2026.e01035_bib127","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1158\/1078-0432.CCR-16-0506","article-title":"A cancer research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma","volume":"22","author":"Rampling","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01035_bib128","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99145","article-title":"Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial","volume":"3","author":"Ji","year":"2018","journal-title":"JCI Insight"},{"issue":"7738","key":"10.1016\/j.neurot.2026.e01035_bib129","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nature"},{"issue":"7738","key":"10.1016\/j.neurot.2026.e01035_bib130","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib131","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.neurot.2026.e01035_bib132","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1158\/1078-0432.CCR-19-0261","article-title":"A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma","volume":"25","author":"Wen","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01035_bib133","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1158\/1078-0432.CCR-16-2057","article-title":"Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination","volume":"23","author":"Batich","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.neurot.2026.e01035_bib134","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1158\/1078-0432.CCR-20-1082","article-title":"Once, twice, three times a finding: reproducibility of dendritic cell vaccine trials targeting cytomegalovirus in glioblastoma","volume":"26","author":"Batich","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib135","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1158\/0008-5472.CAN-17-0469","article-title":"Dendritic cells enhance polyfunctionality of adoptively transferred T cells that target cytomegalovirus in glioblastoma","volume":"78","author":"Reap","year":"2018","journal-title":"Cancer Res"},{"issue":"26","key":"10.1016\/j.neurot.2026.e01035_bib136","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-Cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01035_bib137","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01035_bib138","first-page":"11","article-title":"Potent antitumor efficacy of anti-GD2 CAR T cells in H3K27M+ diffuse midline gliomas","volume":"24","author":"Mount","year":"2018","journal-title":"Nat Med"},{"issue":"7903","key":"10.1016\/j.neurot.2026.e01035_bib139","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"issue":"8046","key":"10.1016\/j.neurot.2026.e01035_bib140","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.neurot.2026.e01035_bib141","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.neurot.2026.e01035_bib142","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"issue":"591","key":"10.1016\/j.neurot.2026.e01035_bib143","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci Transl Med"},{"issue":"14","key":"10.1016\/j.neurot.2026.e01035_bib144","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01035_bib145","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.neurot.2026.e01035_bib146","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01035_bib147","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01035_bib148","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01035_bib149","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/neuonc\/noad052","article-title":"Polio virotherapy targets the malignant glioma myeloid infiltrate with diffuse microglia activation engulfing the CNS","volume":"25","author":"Yang","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib150","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1038\/s41467-021-26003-6","article-title":"An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma","volume":"12","author":"Xu","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib151","doi-asserted-by":"crossref","first-page":"9718","DOI":"10.1038\/s41467-024-54129-w","article-title":"Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRP\u03b3-derived CD47 blocker","volume":"15","author":"Martins","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.neurot.2026.e01035_bib152","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/neuonc\/nov245","article-title":"Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study","volume":"18","author":"Butowski","year":"2016","journal-title":"Neuro Oncol"},{"issue":"22","key":"10.1016\/j.neurot.2026.e01035_bib153","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-23-0576","article-title":"Effective reprogramming of patient-derived M2-Polarized glioblastoma-associated microglia\/macrophages by treatment with GW2580","volume":"29","author":"Fermi","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.neurot.2026.e01035_bib154","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/acn3.70166","article-title":"SYHA1813, A VEGFR and CSF1R inhibitor, in patients with recurrent high-grade gliomas: a multicenter, open-label phase I study","volume":"12","author":"Kang","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"issue":"Supplement_3","key":"10.1016\/j.neurot.2026.e01035_bib155","doi-asserted-by":"crossref","first-page":"iii304","DOI":"10.1093\/neuonc\/noaa222.127","article-title":"EPCT-02. PBTC-051: first in pediatrics phase 1 study of CD40 agonistic monoclonal antibody APX005M in pediatric subjects with recurrent\/refractory brain tumors","volume":"22","author":"Lindsay","year":"2020","journal-title":"Neuro Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.neurot.2026.e01035_bib156","volume":"26","author":"Lindsay","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurot.2026.e01035_bib157","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1522699","article-title":"The C\/EBP\u03b2 antagonist peptide lucicebtide (ST101) induces macrophage polarization toward a pro-inflammatory phenotype and enhances anti-tumor immune responses","volume":"16","author":"Scuoppo","year":"2025","journal-title":"Front Immunol"},{"issue":"16_suppl","key":"10.1016\/j.neurot.2026.e01035_bib158","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.2016","article-title":"Use of lucicebtide (ST101) in glioblastoma patients by antagonism of C\/EBP\u03b2-dependent mesenchymal cell transition and immunosuppressive M2 macrophage polarization","author":"Iwamoto","year":"2025","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.neurot.2026.e01035_bib159","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111003119","article-title":"STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models","volume":"119","author":"Berger","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01035_bib160","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/neuonc\/noad174","article-title":"Indoximod-based chemo-immunotherapy for pediatric brain tumors: a first-in-children phase I trial","volume":"26","author":"Johnson","year":"2024","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.neurot.2026.e01035_bib161","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.ccell.2024.07.007","article-title":"Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD","volume":"42","author":"Shanley","year":"2024","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01035_bib162","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/neuonc\/noab271","article-title":"Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase I trial","volume":"24","author":"Chiocca","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e01035_bib163","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41467-024-45818-7","article-title":"Repeated blood\u2013brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I\/II clinical trial","volume":"15","author":"Carpentier","year":"2024","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01035_bib164","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/s43018-023-00620-0","article-title":"Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade","volume":"4","author":"Goswami","year":"2023","journal-title":"Nat Cancer"},{"issue":"9","key":"10.1016\/j.neurot.2026.e01035_bib165","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s43018-023-00598-9","article-title":"Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response","volume":"4","author":"Mei","year":"2023","journal-title":"Nat Cancer"},{"issue":"2","key":"10.1016\/j.neurot.2026.e01035_bib166","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11060-019-03172-5","article-title":"Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment","volume":"143","author":"Wu","year":"2019","journal-title":"J Neuro Oncol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e01035_bib167","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1158\/2326-6066.CIR-21-0559","article-title":"Circadian regulator CLOCK drives immunosuppression in glioblastoma","volume":"10","author":"Xuan","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"10.1016\/j.neurot.2026.e01035_bib168","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/s41590-023-01605-y","article-title":"Kunitz-type protease inhibitor TFPI2 remodels stemness and immunosuppressive tumor microenvironment in glioblastoma","volume":"24","author":"Pang","year":"2023","journal-title":"Nat Immunol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926002059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:56:44Z","timestamp":1792720604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926002059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":167,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1878747926002059"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01035","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e01035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e01035"}}